Catalog No.
Product Name
Application
Product Information
Citations
-
E3 ligase ligand-Linker Conjugate
(4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 is an E3 ligase ligand-linker conjugate that features the (4R,5S)-Nutlin carboxylic acid component, which targets MDM2. This compound enables the design of PROTACs by linking to a target protein, facilitating targeted protein degradation. It is particularly useful in research applications focused on modulating EZH2 levels and investigating E3 ligase functionalities in cellular systems. -
E3 Ligase Ligand-Linker Conjugate
tert-Butyl (trans-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)carbamate is an E3 ligase ligand-linker conjugate specifically designed for cellular protein degradation applications. This compound features a CRBN-based ligand and a flexible linker, facilitating the synthesis of proteolysis-targeting chimeras (PROTACs). It is ideal for research investigating targeted protein degradation pathways and the development of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-10-bromodecanoic acid is an E3 ligase ligand-linker conjugate that features a VHL ligand and a 10-bromo-decanoic acid linker. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by enabling targeted degradation of specific proteins. It is particularly applicable in the research of protein degradation pathways and the modulation of PI3Kδ activity for therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-F-C-piperazine is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand. This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs). Its unique chemical structure enables targeted degradation of specific proteins, making it a key tool in drug discovery and development, particularly in cancer research and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-pyrrolidine dihydrochloride is an E3 ligase ligand-linker conjugate specifically designed to target cereblon (CRBN). This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted degradation of specific proteins through ubiquitin-proteasome pathways. Its application is crucial in chemical biology and drug discovery research, particularly for studying protein interactions and modulating cellular processes. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-azetidine-CHO is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound includes a cereblon (CRBN)-based ligand and a flexible linker, facilitating the synthesis of PROTACs (proteolysis-targeting chimeras). Its structural components enable effective modulation of protein levels in cellular environments, making it a valuable tool in biochemical research and drug development studies. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-O-7-azaspiro[3.5]nonane serves as an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs) by linking a target protein with an E3 ubiquitin ligase. Its application in targeted protein degradation research underscores its potential to advance therapeutic strategies within the fields of oncology and cellular signaling. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-2,6-diazaspiro[3.3]heptane is an E3 ligase ligand-linker conjugate that utilizes a cereblon (CRBN)-based ligand. This compound is designed for the synthesis of proteolysis targeting chimeras (PROTACs), facilitating targeted protein degradation. Its unique structural features enhance the efficiency of ligand binding and promote the recruitment of E3 ligases for therapeutic strategies in various biological research areas. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C7-amine dihydrochloride functions as an E3 ligase ligand-linker conjugate, integrating the VH032-based VHL ligand with a tailored linker. This compound is specifically designed for use in PROTAC (proteolysis-targeting chimeras) applications, targeting the estrogen-related receptor α (ERRα) for degradation. Its unique structure enables enhanced selective degradation of ERRα, making it a valuable tool for research in targeted protein degradation and related cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 135 is a critical intermediate composed of an E3 ligase ligand and a linker, designed for use in the synthesis of complete PROTAC molecules. This compound facilitates the targeted degradation of proteins, specifically functioning in the context of the pan-KRAS degrader 5. It serves as a valuable tool for researchers investigating targeted protein degradation and related therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG2-C2-CH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC TEAD degrader-1, enabling the effective modulation of protein levels through the ubiquitin-proteasome system. Its utilization in various research settings aids in the study of protein interactions and degradation pathways, offering a valuable tool for advancing targeted therapeutics. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C4-Boc is a conjugate that targets the E3 ligase Cereblon through an innovative linker. This compound facilitates the synthesis of PROTAC CARM1/IKZF3 degrader-1, enabling targeted protein degradation studies. Its primary application lies in the development of novel therapeutics and novel molecular probes in cellular research. -
E3 Ligase Ligand-Linker Conjugate
(S)-Thalidomide-5-fluoro-6-piperazin besylate functions as an E3 ligase ligand-linker conjugate, incorporating a cereblon (CRBN)-based ligand and linker. It is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation in cellular systems. This compound is valuable for research applications focused on protein regulation and therapeutic development in various disease models. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C7-Br is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound incorporates the Thalidomide-derived CRBN ligand along with a versatile linker, facilitating the synthesis of PROTAC constructs. Thalidomide-4-O-C7-Br serves as a crucial component for developing PROTACs aimed at promoting the degradation of specific proteins, such as FAK, thereby advancing research in cellular regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Pip-4-one is an E3 ligase ligand-linker conjugate that consists of a CRBN-based ligand and an optimized linker. This compound is utilized for the synthesis of Proteolysis Targeting Chimeras (PROTACs), which enable targeted protein degradation. Its applications in chemical biology facilitate the study of protein dynamics and the modulation of biological pathways in various research settings. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C5-Br is a synthetic E3 ligase ligand-linker conjugate that features a thalidomide-derived CRBN ligand combined with a versatile linker suitable for PROTAC applications. This compound facilitates the targeted degradation of specific proteins, exemplified by its role in the formation of PROTAC EZH2 Degrader-11. Thalidomide-4-O-C5-Br serves as a valuable tool for researchers investigating targeted protein degradation and the modulation of cellular pathways. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidin-piperazine is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN) ligand and a spacer. This compound is designed for the synthesis of protein-targeting chimeras (PROTACs), enabling the selective degradation of target proteins via the ubiquitin-proteasome system. Its use in research applications includes the investigation of targeted protein degradation mechanisms and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-piperazine-C-piperidine hydrochloride serves as an E3 ligase ligand-linker conjugate, incorporating a CRBN-based ligand and linker. This compound is designed for the synthesis of PROTAC (proteolysis-targeting chimeras), facilitating targeted protein degradation. Its utility lies in advancing research in therapeutic applications that involve modulation of protein homeostasis through targeted neosome pathways. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide 4'-PEG6-azide is an E3 ligase ligand-linker conjugate designed for the targeted recruitment of the CRBN protein. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling selective protein degradation in cellular studies. Its application is essential in research focusing on the modulation of protein levels and the investigation of ubiquitin-proteasome pathways. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-O-piperidine is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC compounds. This reagent features a CRBN-based ligand linked to a piperidine moiety, enabling targeted recruitment of ubiquitin ligases for protein degradation studies. It is valuable for researchers exploring the therapeutic potential of targeted protein modulation and elucidating protein homeostasis mechanisms in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-(1-(3-pyrrolidinylmethyl)piperazine) is an E3 ligase ligand-linker conjugate targeting cereblon (CRBN). This compound enables the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating selective protein degradation. It is valuable for research in targeted protein modulation and the exploration of E3 ligase interactions in cellular pathways. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-Pip-3-hydroxypropanoic acid is an E3 ligase ligand-linker conjugate designed to engage the cereblon (CRBN) E3 ubiquitin ligase. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by linking target proteins to the ubiquitin-proteasome system. Its application in targeted protein degradation research makes it a valuable tool for studying protein regulation and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine-C-COOH is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand and a versatile linker. This compound is designed for the synthesis of PROTACs (proteolysis-targeting chimeras), which facilitate targeted protein degradation. Its utility in chemical biology enables research applications in therapeutic development and the study of protein function and regulation. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 131 is designed as an E3 ligase ligand linked to a chemical moiety, serving as a crucial intermediate in the synthesis of the PROTAC molecule CPD-10. This conjugate facilitates targeted protein degradation by promoting the ubiquitination of specific substrates through E3 ligase recruitment. Its application in research includes the development of PROTACs for investigating protein function and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-(1-(3R-pyrrolidinylmethyl)piperazine)-Boc is an E3 ligase ligand-linker conjugate designed for the targeted protein degradation approach. This compound incorporates a CRBN-based ligand that facilitates the recruitment of E3 ligases for the selective ubiquitination of target proteins. It is primarily utilized in the synthesis of PROTACs, aiding researchers in the development of novel therapeutics that induce targeted degradation of disease-related proteins. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-6-F-5-azetidine-COOH is an E3 ligase ligand-linker conjugate designed for use in PROTAC (PROteolysis TArgeting Chimeras) synthesis. This compound features a CRBN-based ligand that facilitates specific protein degradation through the recruitment of E3 ligases. Its application is crucial for advancing research in targeted protein removal and therapeutic development within the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-C-COOH is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN) ligand and linker moiety. This compound serves as a critical tool for the synthesis of PROTACs (Proteolysis Targeting Chimeras), which are designed for targeted protein degradation. Its versatility makes it valuable in studies focused on protein regulation and therapeutic intervention in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-azetidine is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand. This compound plays a pivotal role in the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating the targeted degradation of specific proteins. Its structure enables efficient binding to E3 ligases, making it a valuable tool for research in protein degradation strategies and therapeutic development. -
E3 Ubiquitin Ligase Ligands and Linkers for PROTACs
6-Aminocaproic acid-(S,R,S)-AHPC-Me is a ligand and linker designed for E3 ubiquitin ligase in proteolysis-targeting chimeras (PROTACs). This compound plays a critical role in the development of targeted protein degradation approaches, making it valuable in tumor research and related applications. Its utilization in synthesizing PVD-06 highlights its importance in advancing therapeutic strategies against cancer. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-CO-C6-COOH is an E3 ligase ligand-linker conjugate featuring a VHL ligand and a linker derived from (S,R,S)-AHPC. This compound facilitates the synthesis of PROTAC molecules, enabling targeted protein degradation. The unique structure promotes selective ubiquitination and subsequent proteasomal degradation of target proteins, providing valuable tools for research in protein regulation and disease model studies. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-Linker Conjugate 113 is an advanced tool designed for targeted protein degradation via the ubiquitin-proteasome system. This conjugate facilitates the recruitment of E3 ligases to specific substrates, thus promoting ubiquitination and subsequent degradation of target proteins. Its utility spans a range of applications, including drug discovery, cellular biology, and understanding protein turnover mechanisms in various disease states. -
Linker-E3 Ligase Ligand Conjugate
Pomalidomide 5-piperidylamine is a linker-E3 ligase ligand conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC PARP1 degrader-2, which selectively promotes the degradation of PARP1 protein. Its utility in research enables the study of targeted degradation pathways and the role of PARP1 in various cellular processes. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-COOH is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN)-based ligand, designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted protein degradation by harnessing the ubiquitin-proteasome system, thus providing a powerful tool for studies in protein regulation and degradation. Its applications extend to drug discovery and the development of novel therapeutic strategies, particularly in oncology and targeted therapy research. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-PEG3-C3 is an E3 ligase ligand-linker conjugate designed to facilitate the targeted degradation of proteins via the PROTAC (Proteolysis Targeting Chimeras) technology. This compound incorporates a VHL ligand and a PEG-based linker derived from (S,R,S)-AHPC, providing enhanced solubility and stability. Its applications include the development of novel therapeutic strategies for diseases associated with protein dysregulation. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-piperidine is an E3 ligase ligand-linker conjugate specifically designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). This compound features a CRBN-based ligand that facilitates targeted protein degradation through the recruitment of the cereblon E3 ligase. Its unique structure enables efficient conjugation, making it a valuable tool for advancing research in targeted protein degradation and therapeutic discovery. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine-NH-Me is an E3 ligase ligand-linker conjugate designed to facilitate the synthesis of PROTACs (proteolysis-targeting chimeras). This compound features a CRBN-based ligand that engages with E3 ubiquitin ligases, enabling the targeted degradation of specific proteins within cellular systems. Its applications in chemical biology and therapeutic development include the study of protein regulation and the discovery of new drug candidates. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 122 is a specialized reagent designed for the synthesis of PROTAC degraders, specifically NR-11c. It combines an E3 ligase ligand with a linker, facilitating targeted protein degradation through the ubiquitin-proteasome system. This compound is essential for studies focused on E3 ligase-mediated degradation pathways and therapeutic applications in targeted cancer therapies. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-1-(piperidin-4-ylmethyl)piperidine is an E3 ligase ligand-linker conjugate designed for use in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound features a CRBN-based ligand, facilitating the selective recruitment of target proteins for ubiquitination and subsequent degradation. It is a valuable tool for researchers studying targeted protein degradation and its therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
E3 ligase Ligand PG-piperidine-C2-OH is a conjugate designed for E3 ligase targeting, featuring a CRBN-based ligand linked to a piperidine moiety. This versatile linker compound serves as a crucial component in the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating the targeted degradation of proteins. Its application in chemical biology research enables the precise modulation of protein levels, contributing to studies in cancer therapeutics and other disease areas. -
E3 Ligase Ligand-Linker Conjugate
3-(2,6-Difluoro-4-(4-(2-hydroxyethyl)piperidin-1-yl)phenyl)piperidine-2,6-dione functions as an E3 ligase ligand-linker conjugate with a CRBN-based ligand. This compound is designed for the synthesis of PROTACs (proteolysis-targeting chimeras), serving as a valuable tool in targeted protein degradation studies. It can be utilized in research applications involving modulation of cellular pathways and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG2-OMs is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the recruitment of the cereblon (CRBN) E3 ligase. This compound effectively enhances the efficacy of proteolysis-targeting chimeras (PROTACs), specifically enabling the degradation of epidermal growth factor receptor (EGFR) in research applications. Its versatile functionality makes it a valuable tool in studies focused on protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-azetidine is a conjugate that targets the E3 ligase cereblon (CRBN) through its ligand-linker composition. This reagent is essential for the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating targeted protein degradation research. Its application supports studies in protein regulation and therapeutic development in various disease contexts, including cancer and neurodegenerative disorders. -
E3 Ligase Ligand-Linker Conjugate
KRAS G12C degrader-2 is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand and a functional linker. This compound facilitates the development of PROTAC (proteolysis-targeting chimeras), enabling targeted degradation of KRAS G12C-mutant proteins. It is a valuable tool for researchers investigating the therapeutic potential of targeted protein degradation in cancer treatment. -
E3 Ligase Ligand-Linker Conjugates
(3S)Lenalidomide-piperazine-C-piperidine acts as a ligand-linker conjugate targeting E3 ubiquitin ligases. This compound facilitates the design and synthesis of PROTACs, specifically enabling the development of PROTAC ER Degrader-11. Its application in targeted protein degradation research makes it a valuable tool for studying ubiquitin-mediated cellular processes. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-6-F-5-piperazine benzenesulfonate is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a linker structure. This compound is designed for the synthesis of proteolysis-targeting chimeras (PROTACs), which facilitate targeted protein degradation. It serves as a valuable tool in drug discovery and development by enabling the selective modulation of protein levels within cellular systems. -
Crosslinker-E3 Ligase Ligand Conjugate
Pomalidomid-C6-PEG3-butyl-N3 is a crosslinker-E3 ligase ligand conjugate designed for click chemistry applications. This reagent features an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and ring strain-promoted alkyne-azide cycloaddition (SPAAC) reactions. Pomalidomid-C6-PEG3-butyl-N3 serves as an essential building block for the development of proteolysis-targeting chimeras (PROTACs) and targeted protein degraders, facilitating advancements in targeted protein degradation research. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-C-piperazine is an E3 ligase ligand-linker conjugate designed for the targeted degradation of specific proteins. The compound features a cereblon (CRBN)-based ligand, enabling the synthesis of PROTAC (Proteolysis Targeting Chimera) molecules. This reagent is valuable for research applications involving protein modulation and the study of protein homeostasis pathways. It may facilitate the development of targeted therapies in various disease models, including cancer. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-propargyl-NHCH3 is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a propargyl linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs) by promoting targeted protein degradation. Its applications include advancing research on protein regulation and therapeutic development in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-S-COOH is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand and a linker moiety. This compound facilitates the synthesis of Proteolysis Targeting Chimeras (PROTACs), which are innovative tools for targeted protein degradation. Its applications include fundamental research in cellular signaling pathways, drug development, and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
(R,S,S)-VH032-PEG5-N3 is an E3 ligase ligand-linker conjugate that combines a VHL ligand, derived from VH032, with a five-unit PEG linker. This compound serves as a versatile click chemistry reagent featuring an azide group, which facilitates copper-catalyzed azido-alkyne cycloaddition (CuAAc) when interacting with alkyne-containing molecules. Additionally, it is capable of undergoing strain-promoted azide-alkyne cycloaddition (SPAAC) with compounds containing DBCO or BCN groups, making it valuable for targeted protein degradation studies and related applications in chemical biology.
